Mycophenolic Acid Accord

Mycophenolic Acid, the active ingredient in Mycophenolic Acid Accord, is an immunosuppressant (antimetabolite) presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat selected autoimmune disorders such as lupus nephritis and vasculitis in adult patients. The product conforms to European Union marketing standards and is available by prescription only.

GNH USA supplies Mycophenolic Acid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolic Acid is used to modulate immune responses in conditions where excessive lymphocyte activity is harmful.

- Organ transplant rejection: helps prevent the immune system from attacking the transplanted organ. - Lupus nephritis: reduces kidney inflammation caused by systemic lupus erythematosus. - Vasculitis: diminishes inflammation of blood vessels in various autoimmune vasculitic disorders.

Mycophenolic Acid may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Headache: mild to moderate intensity. - Infections: increased susceptibility to upper respiratory or urinary tract infections. - Anemia: reduced red blood cell count causing fatigue. - Elevated liver enzymes: mild transaminase elevations. - Rash: mild skin irritation or itching.

Serious or Rare Side Effects: - Bone marrow suppression: severe leukopenia, neutropenia, or thrombocytopenia. - Opportunistic infections: including fungal or viral infections such as cytomegalovirus. - Malignancies: increased risk of lymphoproliferative disorders. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Hepatotoxicity: significant liver injury or hepatitis. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should assess baseline laboratory values and monitor patients regularly.

- Monitor blood counts: check complete blood count periodically to detect bone marrow suppression. - Assess renal function: adjust dosing in patients with impaired kidney function. - Avoid in pregnancy: drug is contraindicated due to teratogenic risk. - Use effective contraception: both male and female patients of reproductive potential must employ reliable birth control. - Review concomitant medications: avoid drugs that may increase mycophenolic acid exposure. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Mycophenolic Acid can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine, tacrolimus: may increase mycophenolic acid exposure and toxicity. - Live vaccines: heightened risk of severe infection due to immunosuppression. - Antacids containing aluminum or magnesium: can reduce oral absorption of the drug.

Moderate Interactions (Monitor Closely): - Rifampin: may lower mycophenolic acid plasma levels, reducing effectiveness. - Warfarin: potential alteration of anticoagulant effect, requiring INR monitoring. - Cholestyramine: may decrease drug exposure by binding in the gut.